To,

May 29, 2026

National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E),
Mumbai- 400051

Script Name: MAITREYA

ISIN: INE0PLQ01011

Sub: Outcome of the Board Meeting held on Friday, 29th May, 2026

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. May 29, 2026, inter-alia considered and approved the followings:

1. Audited Standalone and Consolidated Financial Results for half year and year ended March 31, 2026. Pursuant to Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed herewith the following:

   (a) Statement of Audited Standalone and Consolidated Financial Results for the half year and year ended March 31, 2026.

   (b) Audit Reports, issued by Statutory Auditors of the Company, on the Audited Financial Results of the Company for the half year and year ended March 31, 2026.

   (c) A confirmation pursuant to regulation 33(3) (d) of SEBI (LODR) Regulations 2015 from the CFO of the Company, declaring that the statutory auditors have expressed an unmodified audit opinion in respect of financial results.

2. Appointment of M/s. R P V & Company (FRN: 0134844W), Chartered Accountants as the Internal Auditor of the Company for the financial year 2026-27.

3. Re-appointment of Jaisal Mohatta, Partner of JDM and Associates LLP, Practicing Company Secretaries (Firm Registration No. L2025GJ019100 / Peer Review Certificate No. 6787/2025) as Secretarial Auditor of the Company for the financial year 2026-27.

4. Took note of the resignation of Dr. Pranav Rohitbhai Thaker (DIN: 07602708) from the position of Whole-time Director of the Company w.e.f. the closure of business hours on 25th May, 2026.

5. Redemption of 90,000 6% Non-Convertible Cumulative Redeemable Preference Shares

The particulars / details with respect to re-appointment of Secretarial Auditor and Appointment Internal Auditor of the Company as required under SEBI Circular No. SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated 13th July 2023 are enclosed as **Annexure A**.

The aforesaid Board Meeting commenced at 03:00 p.m. (IST) and concluded at 04:20 p.m. (IST).

We request you to kindly take the above on record.

Thanking You,

Yours faithfully,

For **Maitreya Medicare Limited**

SURANA KASHISH
Digitally signed by SURANA KASHISH
Date: 2026.05.29 16:43:16 +05'30'

Kashish Surana
Company Secretary & Compliance Officer
ACS- 76674

Encl. as above

Annexure-A

Sr. No.	Particulars	M/s. JDM and Associates LLP
1	Reason for change viz. ~~appointment,~~ reappointment, ~~resignation, removal, death of otherwise~~	Re-appointment of Jaisal Mohatta, Partner of JDM and Associates LLP, Peer Reviewed Firm of Company Secretaries in Practice (Firm registration number: L2025GJ019100), as Secretarial Auditors of the Company.
2	Date of ~~appointment~~/ re-appointment/~~cessation (as applicable)~~ & term of ~~appointment~~/reappointment	The Board at its meeting held on May 29, 2026, approved the re-appointment of Jaisal Mohatta, Partner of JDM and Associates LLP as Secretarial Auditors, for the financial year 2026-27.
3	Term of ~~Appointment~~ /re-appointment	1 year
4	Brief Profile	JDM and Associates LLP (Firm Registration No. L2025GJ019100) is **Peer reviewed firm** and is an integrated corporate service firm focused on Corporate Laws & Secretarial Compliances, Due Diligence, Certifications, XBRL filing, Startup Consultancy Services, Regulatory Authority Services, Secretarial Audits, Corporate Governance Audit, IPO Pre-Post Due-diligence services and related matters.
5	Disclosure of Relationships between directors (in case of appointment of a director).	Not Applicable
6	Information as required pursuant to BSE Circular ref. no. LIST/COMP/14/ 2018-19 and NSE ref. no. NSE/CML/2018/24, dated June 20, 2018.	Not Applicable

Sr. No.	Particulars	M/s. R P V & Company
1	Reason for change viz. appointment, ~~reappointment, resignation, removal, death of otherwise~~	To comply with the provisions of the Companies Act, 2013 & SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, upon recommendation of Audit Committee, the

		Board of Directors at its meeting held on 29th May, 2026, Appointed M/s. R P V & Company as Internal Auditor of the Company, for a period of 1 (One) year.
2	Date of appointment/ ~~re-appointment/cessation~~ (as applicable) & term of appointment~~/reappointment~~	Appointment of M/s. R P V & Company as Internal Auditor of the Company, shall be for the financial year 2026-27.
3	Term of Appointment ~~/re-appointment~~	1 Year
3	Brief Profile (in case of appointment)	M/s. R P V & Company, a firm of Chartered Accountant being the Internal Auditor of the Company is a good leader in providing expert and professional services with due care of professional ethics.
4	Disclosure of Relationships between directors (in case of appointment of a director).	Not Applicable

Multi Superspeciality Hospital & Research Centre
Healing by Heart

To,

May 29, 2026

National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E),
Mumbai- 400051

Script Name: MAITREYA

Dear Sir,

Sub: Declaration pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Amendment Regulation, 2016

I, Narendra Singh Tanwar, Chief Financial Oficer of Maitreya Medicare Limited, having it Registered Office at Nr Someshwara Char Rasta, Um Road, Surat, Gujarat, India, 395007 hereby declare that the Statutory Auditors of the Company M/s. Saherwala & Co. have issue an Audit Report with unmodified opinion on the Annual Audited Financial Result of the Company (Standalone & Consolidation) for the half year and year ended on 31st March, 2026.

The Disclosure is given in compliance to Regulation 33(3)(d) of SEBI (LODR) Regulation, 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulation, 2016 vide circular No CIR/CFD/CMD/56/2016 dated 27th May, 2016.

Kind takes this declaration on your record.

Your Sincerely,
Maitreya Medicare Limited

Narendra Singh Tanwar
Managing Director & CFO
DIN: 08459007

INDEPENDENT AUDITOR'S REPORT

To the Members of MAITREYA MEDICARE LIMITED

Formerly known as MAITREYA MEDICARE PRIVATE LIMITED

Report on the Audit of the Standalone Financial Statements

1. We have audited the accompanying Standalone financial statements of Maitreya Medicare Limited (*Formerly known as Maitreya Medicare Private Limited)*, which comprise the balance sheet as at 31st March 2026, and the statement of profit and loss, statement of cash flows for the period then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Standalone Financial Statements

2. The management and Board of Directors of the Company are responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ('the act') with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with rule 7 of Companies (Accounts) Rules, 2014. This responsibility includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of

SAHERWALA & CO. SURAT Chartered Accountants

5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Opinion

6. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at 31st March 2026, its ~~profit~~/loss and its cash flows for the period ended on that date.

Report on Other Legal and Regulatory Requirements

7. As required by the Companies (Auditor's Report) Order, 2020 issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, and on the basis of such checks of the books and records of the company as we considered appropriate and according to the information and explanations given to us, we give in the "Annexure A" a statement on the matters Specified in paragraphs 3 and 4 of the Order report as per this order.

8. As required by section 143(3) of the Act, we further report that:

a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;

b) in our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;

c) the Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account;

SAHERWALA & CO. SURAT. Chartered Accountants

d) in our opinion, the aforesaid Standalone financial statements comply with the applicable Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules 2014.

e) on the basis of written representations received from the directors as on March 31, 2026, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026, from being appointed as a director in terms of Section 164(2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

g) In our opinion and to the best of our information and according to the explanations given to us, we report as under with respect to other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014:

   i. The Company does not have any legal pending court litigations which would impact its financial position; except cases under the consumer court filed by patients against various insurance companies in which company is co-respondent. (Please see Notes No. 31.24 to the Balance Sheet)

   ii. The Company did not have any long-term contracts including derivative contracts; as such the question of commenting on any material foreseeable losses thereon does not arise;

SAHERWALA & CO. SURAT Chartered Accountants

iii. There has not been an occasion in case of the Company during the period under report to transfer any sums to the Investor Education and Protection Fund. The question of delay in transferring such sums does not arise.

h) The company, has used such accounting software for maintaining its books of account which:

i. Has a built-in Feature of recording audit trail (edit log) facility and

ii. The audit trail has operated throughout the year for all transactions recorded in the software and

iii. The audit trail feature has not been tampered with.

iv. The audit trail has been preserved by the company as per the statutory requirements for record retention.

FOR SAHERWALA & CO
CHARTERED ACCOUNTANTS
FRN 108969W

SAHERWALA & CO. SURAT Chartered Accountants

PLACE: SURAT
DATE: 29.05.2026

E. O. Saherwala

ESMAYEEL O. SAHERWALA
PARTNER
M. No. 122386
UDIN: 26122386YLRSTC9026

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298

STATEMENT OF STANDALONE AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2026

	Particulars	Half year ended			For the year ended March 31, 2026	For the year ended March 31, 2025
		March 31, 2026	September 30, 2025	March 31, 2025		
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from operations	2,094.32	2,327.80	2,223.34	4,422.12	4,441.32
II	Other income	59.12	14.09	29.70	73.21	43.98
III	Total Revenue (I + II)	2,153.44	2,341.89	2,253.04	4,495.33	4,485.30
IV	Expenses:					
	(a) Cost of Raw Material Consumed	259.46	213.65	127.73	473.11	286.80
	(b) Purchases of Stock-in-Trade	215.64	257.92	325.66	473.56	586.29
	(c) Changes in inventories of stock-in-trade	0.71	-0.15	-1.65	0.56	(1.03)
	(d) Employee benefits expense	258.71	250.46	278.32	509.17	521.88
	(e) Finance costs	91.18	36.74	37.09	127.92	75.44
	(f) Depreciation and amortization expense	66.62	71.47	71.14	138.09	134.59
	(g) Other expenses	1,405.47	1,489.76	1,278.01	2,895.23	2,559.09
	Total Expenses	2,297.79	2,319.85	2,116.30	4,617.64	4,163.06
V	Profit before prior-period items and tax (III - IV)	(144.35)	22.04	136.74	(122.51)	322.25
VI	Prior-Period Items	11.79			11.79	
VII	Profit before tax (V- VI)	(156.14)	22.04	136.74	(134.10)	322.25
VIII	Tax expense:					
	(1) Current tax expense	-5.73	5.73	30.99	-	80.75
	(2) Deferred tax expense/(credit)	3.13	1.58	-	4.71	1.13
	(3) Short/(Excess) provision of tax for earlier years	-6.34		50.42	(6.34)	50.42
		(8.94)	7.31	81.41	(1.63)	132.29
	Dividend on Preference Shares	-			-	
IX	Profit from continuing operations (VII-VIII)	(147.20)	14.73	55.33	(132.47)	189.96
X	Paid-up Equity Share Capital (Face Value of ₹ 10/- each)	677.60	677.60	677.60	677.60	677.60
XI	Reserves excluding revaluation reserves as per balance sheet of previous accounting year					
XII	Earnings per Equity Share (Non-Annualised) :- Face Value of ₹ 10/- each					
	(Pre-bonus)					
	- Basic					
	- Diluted	(2.17)	0.22	0.82	(1.95)	2.80
	(Post-bonus)					
	- Basic					
	- Diluted					

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

SAHERWALA & CO. SURAT Chartered Accountants

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN: 26122386YLRSTC9026

NARENDRA TANWAR
DIN - 00084590007
MD AND CFO

VIMAL PATEL
DIN- 08458999
Wholetime Director

Kashish Surana
M.NO - A76674
Company Secretary

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
AUDITED BALANCE SHEET AS ON 31st March 2026
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

Particulars	Note No.	As at 31st March 2026	As at 31st March 2025
I. EQUITY & LIABILITIES			
(1) Shareholders"s Funds			
a) Share capital	1	115523	120923
b) Reserve & Surplus	2	186593	199841
c) Money received against share warrants			
(2) Share application money pending allotment			
(3) Non-Current Liabilities			
a) Long-term Borrowings	3	216977	19594
b)Deffered tax liability (Net)	4	7878	6953
c)Other long term Liabilities			
d)Long term Provisions			
(4) Current Liabilities			
a) Short-term Borrowings	5	11786	15744
b) Trade payables			
(A) total outstanding dues of micro enterprises and small enterprises; and	6	4696	2876
(B) total outstanding dues of creditors other than micro enterprises and small enterprises.		28045	24937
c) Other curent Liabilites	7	61404	45193
d) Short term Provisions	8		8075
Total		632902	444136
II. Assets			
(1) Non-current assets			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment	9	329784	118212
(ii) Intangible Assets		1149	1445
b) Non Current Investments	10	75730	75830
c) Deffered tax asset (net)			
d) Long term loans and advances	11	54912	52238
e) Other Non current assets	12	10859	12722
(2) Current assets			
a) Current Investments	13	522	422
b) Inventories	14	7740	4798
c) Trade receivables	15	116155	151850
d) Cash & Cash equivalents	16	28937	19090
e) Short-term loans and advances	17	3794	5019
f) Other current assets	18	3321	2510
Total		632902	444136

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

SAHERWALA & CO. SURAT Chartered Accountants

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN : 26122386YLRS[illegible]

For MAITREYA MEDICARE LIMITED

NARENDRA TANWAR
DIN - 00084599007
MD AND CFO

VIMAL PATEL
DIN - 08458999
Wholetime Director

Kashish Surana
M.No. A76674
Company Secretary

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
AUDITED CASH FLOW STATEMENT
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

PARTICULARS		As at 31st March 2026		As at 31st March 2025	
A. Cash Flow from Operating Activities:					
Profit Before exceptional and extradinary items and tax			-12232		32224
Adjustments for :					
Depreciation		13809		13459	
Interest Income		-2387		-695	
Gratuity				1677	
Interest & Finance Charges Paid		12792		7544	
Profit on sale of investment				-225	
Prior Period Adjustment - gst		-725			
Reversal of Previous Year Income Tax		634			
Profit on sale of Fixed Assets		-20			
			24104		21761
Operating Profit before Working Capital Changes			11872		53985
Adjustments for :					
Increase / Decrease in Inventories		-2942		-113	
Increase / Decrease in Short-term loans and advances		1225		-3478	
Increase / Decrease in Trade Receivables		35695		-21142	
Increase / Decrease in Trade Payables		4928		4312	
Increase / Decrease in other Current Assets		-811		3312	
Increase / Decrease in Other Non Current Assets		1864		4174	
Increase/Decrease in Provision		-8075		-3918	
Increase/Decrease in short term Borrowings		-3957		2143	
Increase/Decrease in other current liabilities		16211	44137	25559	10849
Cash Generated from Operations			56009		64834
Direct Taxes Paid (Net)		1203.17	1203	14547	14547
Net Cash inflow in Operating Activities		Total A	54806	Total A	50287
B. Cash Flow from Investing Activities:					
Purchases of Fixed assets		-225197		-23741	
Purchase of Investment		-100		-44206	
Capital Government Grant of Fixed Assets					
Loans given to Associates and Subsidiaries		-1471		-9073	
Repayment of Loans given to Associates and Subsidiaries					
Interest Income		2387		695	
Gain on Sale of Fixed Assets					
Sale of Fixed Assets		131			
Gain on Sale of Investment					

SAHERWALA & CO.
SURAT
Chartered Accountants

Sale of Investment			100	-224150		4300	-72026
Net Cash used in Investing Activities		Total B		-224150	Total B		-72026
C. Cash Flow from Financing Activities:							
Issue of Equity Capital							
Share Premium							
Dividend							
Issue of Preference Shares							
Redemption of Preference shares			-5400			-800	
Repayment of Borrowing			197383			-7441	
Interest & Finance Charges Paid			-12792	179191		-7544	-15785
Net Cash from Financing Activities		Total C		179191	Total C		-15785
Net Increase /(decrease) in cash and cash equivalents (A+B+C)		Total (A+B+C)		9847	Total (A+B+C)		-37524
Opening Cash and Cash equivalents				19090			56614
Closing Cash and Cash equivalents				28937			19090

Notes :

(i) Figures in brackets represent outflow.

(ii) The above Cash Flow statement has been prepared under the indirect method set out in AS-3 notified under Section 133 of the Companies Act,2013

(iii) Cash and Cash Equivalents represent cash and bank balances.

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

SAHERWALA & CO. SURAT Chartered Accountants

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29th May 2026, Surat.
UDIN : 26122386 YLRSTC9026

For MAITREYA MEDICARE LIMITED

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

VIMAL PATEL
DIN- 08458999
Wholetime Director

Kashish Surana
M. No. A76674
Company Secretary

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298
STATEMENT OF STANDALONE AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2026

Notes to audited standalone financial results

1 The above audited Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors in their respective meeting held on May 29, 2026.

2 The Results for the half year and year ended March 31, 2026 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.

4 The figures for the half year ended September 30, 2025 limited reveiwed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

5 The figures for the half-year ended March 31, 2026 are unaudited published figures in respect of the half-year ended September 30, 2025 limited reveiwed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

6 The figures for the half-year ended March 31, 2026 are balancing figure between unaudited figures in respect of the half year ended september 30, 2025 limited reveiwed by the statutory auditors and audited figures for the financial year ended March 31, 2026 .The comparative results for the year ended March 31, 2026 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2026 are audited published figures in respect of the year ended March 31, 2026 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

7 The Company is engaged in the business of providing healthcare services and products. Hence, the Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.

8 During the year ended March 31, 2024, the company has issued 18,16,000 equity shares of ₹ 10 each at a premium of ₹ 68 - ₹ 72 each by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on November 7, 2023.

SAHERWALA & CO. SURAT Chartered Accountants

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298
STATEMENT OF STANDALONE AUDITED RESULTS FOR THE YEAR ENDED MARCH 31, 2026

Notes to audited standalone financial results

9 The company has utilised proceeds from IPO as per the object clause of the prospectus as detailed below:

S. No.	Object of the Issue	Allocated Amount (₹ in Thousands)	Amount utilised till MARCH 31, 2026 (₹ in Thousands)	Amount unutilised till MARCH 31, 2026 (₹ in Thousands)	Remarks (if any)
1	Making investment through Equity in the subsidiary named 'Maitreya Hospital Private Limited' for setting up Hospital at Valsad, Gujarat.	75,000.00	75,000.00	-	Remaining amount is kept with banks.
2	Redemption of part of issued Non-Convertible Redeemable Preference Shares	10,000.00	9,600.00	400.00	
3	Funding the working capital requirements of the company	50,000.00	50,000.00	-	
4	General Corporate Expenses	7,445.60	7,445.60	-	
5	Public Issue Expenses	6,466.40	6,466.40	-	
	Total	148,912.00	148,512.00	400.00	

As Per Our Report of Even Dated Annexed
Saherwala & Co.
FRN 108969W

SAHERWALA & CO. SURAT Chartered Accountants

(ESMAYEEL O. SAHERWALA)
Chartered Accountant
M. NO. 122386
29nd May 2026, Surat.
UDIN: 26122386YLRSTC9026

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO

VIMAL PATEL
DIN- 08458999
Wholetime Director

Kashish Surana
M.No. A76674
Company Secretary